Black Friday saleUp to 70% OFF
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

PFIZER SANTA RALLY?Pfizer Pfizer Pfizer where do i start? over the past month Pfizer has been on an uptrend. good news bad news omicron covid etc. this thing just keeps going and i do not think it’s done. i have been scalping this over the past two weeks and on Friday we closed on an inside bar on the 30-minute window which we can see is a period of consolidation. i think Pfizer break outs from here. i am typing my ideas after a long 10-hour shift so I will try to just list out my indicators and why i say it will break out from here. also, i am a beginner so bear with me. - I use Wyse trade fib retracement between .618 and .50 for confirmation on entries. using this fib from that gap down on the 21st shows us that we have a solid entry for calls here. that paired up with the 9ema touching the inside bar that we closed with on the last trading day gives me more conviction to go long on this trade. - also, Pfizer pill is now a thing so that’s even more bullish if that works. - to get more technical price bounced back to the 58.70 level which is a newly formed level of support over the past week coming off all-time highs. - using the tradingwarz fib retracement after the price came back to support the apparent uptrend that was coming, shorts tried to short this down again to break support but that didn’t happen. the fib shows us that we fell a little under the .78 on the 30 min chart. - considering that we are on this same type of scenario now I think that a price target following the fib we could see mid 62 or even 63s this week on Pfizer let’s see how this plays out.
NYSE:PFELong
by kimololaurian
Possible Pfizer Play AlertPfizer has had exponential growth over the past few months with delta variant and most recent omicron variant. Through these ideas we have seen billions of vaccines purchased by other countries and the United States. U.S just administered 500 million doses along with that the FDA just gave the green light to oral antiviral pill. We see a double touch and fall leading to a big jump after a consolidation period in the end of November to early December and right now we are sitting in that exact same bout again and all these purchases of vaccines and antiviral pills being released. Its prominent that Pfizer is bound to reach new highs especially within the early months of 2022. First few calls initiated at 60.3 and a load in the 61.55 zone as we break resistance lines. Stikes: January 28 2022-63 dollar calls- 20% chance of profit- Greeks showing decline of .03 a day with a delta of roughly .3 off the dollar jump
NYSE:PFELong
by haydencrann
Pretty big pullback on Pfizer. Will it recover?I find it quite interesting how these vaccine stocks (pretty much all of the Covid ones) have taken such a big hit on the concern about how effective any boosters might be. Most governments globally on behalf of their citizens are trying to bulk purchase as many doses as they can and there is simply not enough supply. I'd expect to see a recovery, but the main bit of news I want to keep an eye out for is the first one out of say Moderna and Pfizer who creates an oral booster type tablet. Worth a look.
NYSE:PFELong
by zAngus
$PFE keep an eye on it.$PFE has been trending up for the past few weeks. mostly probably because of the covid variant and news. today it just reach the ATH and could possibly continues when they release a news for oral medication for covid. average move of this stock is about .70 to $2.00 depending on a day. on a smaller time frame, the momentum is almost reaching the exhaustion. possible Put play tomorrow as people take profits after reaching all time high. Hello Guys, welcome to this free and technical analysis. ( mostly momentum play ) I am going to explain where I think this stock is going to go over the next day or week play and where I would look for trading opportunities. If you have any questions or suggestions which stock I should analyze, please leave a comment below. If you enjoyed this analysis, I would definitely appreciate it, if you smash that LIKE button and maybe consider following my channel. Thank you for watching and stay tune.
NYSE:PFEShort
by CHRIS_B58
2
LongPopular stock at the moment. The demand for medical products will still be stably high. Price is breaking through another resistance. Expect higher targets: first 60, 62 ❤️ If you find this helpful and want more FREE forecasts in TradingView . . . . . Please show your support back, . . . . . . . . Hit the 👍 LIKE button, . . . . . . . . . . . Drop some feedback below in the comment! ❤️ Your Support is very much 🙏 appreciated!❤️ 💎 Want us to help you become a better Stock trader? Now, It's your turn! Be sure to leave a comment let us know how do you see this opportunity and forecast.
NYSE:PFELong
by QuantumLabSignals
1
Pfizer | Fundamental Analysis | LONG SETUP | MUST READ 🔔Some people say that the Chinese word for "crisis" is composed of two characters, one meaning "danger" and the other meaning "opportunity. In fact, this is not the case. Nevertheless, the word often hits the mark. While many crises carry danger, they also often present opportunities. In the case of COVID-19, we can certainly see this happening. To date, more than 5 million people worldwide have died from this viral infection. At the same time, numerous businesses made a lot of money during the pandemic by selling personal protective equipment, tests, therapies, and vaccines. None of them benefited more financially than Pfizer. In the third quarter alone, the company reported $13 billion in sales of its COVID-19 Comirnaty vaccine. SVB Leerink analyst Jeffrey Porges estimates that Pfizer expects to make a staggering $131 billion on sales of the COVID-19 vaccine by the end of next year. But is this pharmaceutical company stock worth buying? Let's first look at how Pfizer could make $160 billion on coronavirus over the next two years. First, we need to consider the company's projected revenue of $36 billion in 2021 from Comirnaty. Porges believes that sales of the vaccine will actually be much higher this year. He expects that approvals and authorizations in many countries for booster doses and for children could boost Comirnaty's total worldwide sales to $59 billion in 2021. The Wall Street analyst expects vaccine sales to drop to about $48 billion next year. So by the end of 2022, Pfizer's revenue from Comirnaty sales will be $107 billion. But Comirnaty probably won't be Pfizer's only source of revenue from COVID-19. The company hopes to soon get emergency approval and approval for the oral antiviral drug Paxlovid in the U.S. and other countries. Purges predicts that sales of Pfizer's COVID-19 pills could be about $95 million this year and $24 billion next year. If you add it all up, Pfizer's total revenue from COVID-19 sales would be about $131 billion over two years. Pfizer shares the profits from the sale of Comirnaty with its partner BioNTech. Although the company's revenue will be huge, its profits from the vaccine will not be as large. Sales of the COVID-19 vaccine are also likely to be lower in 2023. Porges, however, predicts that Paxlovid sales will grow to $33 billion in 2023. After 2023, though, the picture becomes less cheerful. Many investors speculate that COVID-19 will be like the flu, requiring annual vaccinations. But it is too early to judge whether this will actually be the case. If not, Pfizer's revenues will fall markedly over the next few years. Looking ahead, Pfizer faces a patent cliff beginning in 2026. Several of the company's currently best-selling drugs will lose patent exclusivity in the second half of this decade. Despite these potential problems, it should be noted that there are three reasons why Pfizer stock is still worth buying. Let's start with the most compelling one on the list, the dividend. Currently, Pfizer's dividend yields just under 3%. Given the cash flow the company will generate, there is a good chance that the dividend will increase. Pfizer is also predicted to use its growing cash reserves to make business development deals. The company is expected to license more promising drugs developed by other drugmakers. In addition, many believe that Pfizer will make a major acquisition in the not-too-distant future. The right deals could go a long way toward offsetting the impact of the patent cliff, which is looming in a few years. Finally, there is the possibility that sales of Comirnaty (or its successors) and Paxlovid will remain strong for a long time to come. COVID-19 could become endemic and bring Pfizer much more money over the next decade than anyone expects. Given that Pfizer made $13 billion on sales of its coronavirus vaccine in the third quarter alone, it's understandable why investors are wary of the rapidly evolving threat posed by the new variant, dubbed Omicron. If Omicron proves to be as insidious as early reports suggest, it could well become a serious problem for vaccinated people and vaccine manufacturers worldwide. But the fear of Pfizer's defeat of Omicron is quite premature. In fact, there is probably no company in a better position to solve such a problem as a new option, as an opportunity to rise to the next level. The dangers of this crisis may not go away. And the opportunities for Pfizer may not disappear either.
NYSE:PFELong
by FOREXN1
5